b85 percent of the lung cancer cases are of the non-small-cell lung carcinoma (NSCLC) type which is not sensitive to chemotherapy./b Hence, NSCLC therapies are usually based on drug treatment. A commonly used drug for the treatment of NSCLC is alectinib which acts on the gene rearrangement known as ALK. ALK rearrangement is seen in 3 to 5 percent of NSCLC patients.
Alectinib belongs to a class of drugs known as ALK tyrosine kinase inhibitors. In 25 percent of the patients, secondary cancer ...
b85 percent of the lung cancer cases are of the non-small-cell lung carcinoma (NSCLC) type which is not sensitive to chemotherapy./b Hence, NSCLC therapies are usually based on drug treatment. A commonly used drug for the treatment of NSCLC is alectinib which acts on the gene rearrangement known as ALK. ALK rearrangement is seen in 3 to 5 percent of NSCLC patients.
Alectinib belongs to a class of drugs known as ALK tyrosine kinase inhibitors. In 25 percent of the patients, secondary cancer ...